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Abstract
Background: Environmental factors are an integral component in the pathogenesis of inflammatory bowel disease
(IBD). There is an increasing interest in nutritive components. While the potential disease-modifying role of coffee
has been intensively investigated in a variety of gastrointestinal diseases, the data on the potential impact on IBD is
very limited. We aimed to determine the patients’ perspective on coffee consumption in IBD.
Methods: We conducted a questionnaire among IBD patients in Switzerland, assessing key questions regarding
coffee consumption. Descriptive statistics including chi square testing were used for analysis of questionnaire data.
Results: Among a total of 442 patients 73 % regularly consume coffee. 96 % of patients attributing a positive and
91 % of patients attributing no impact of coffee intake on IBD regularly drink coffee and surprisingly even 49 % of
those patients that assign a negative impact on disease symptoms. Among those patients refraining from regular
coffee intake 62 % are convinced that coffee adversely influences intestinal symptoms, significantly more in Crohn’s
disease (CD) than in ulcerative colitis (UC) (76 % vs. 44 %, p = 0.002). In total, 38 % of all study subjects suppose that
coffee has an effect on their symptoms of disease, significantly more in CD (54 %) compared to UC patients (22 %,
p < 0.001). Moreover, while 45 % of CD patients feel that coffee has a detrimental influence, only 20 % of UC
patients share this impression (p < 0.001).
Conclusion: Two thirds of IBD patients regularly consume coffee. More than twice as many CD compared to UC
patients attribute a symptom-modifying effect of coffee consumption, the majority a detrimental one. However, this
negative perception does not result in abstinence from coffee consumption.
Background
A variety of environmental and genetic factors, an altered
intestinal microbiota, and aberrant immune responses
have been considered as the major etiologic components
in inflammatory bowel disease (IBD), a group of chronic
inflammatory diseases of the gastrointestinal tract (GIT),
including Crohn’s disease (CD) and ulcerative colitis
(UC) [1, 2].
The effect of smoking – the most profoundly investi-
gated environmental factor in IBD - has already been
known for decades [3]. However, many others have been
explored, such as oral contraceptives [4, 5], appendectomy
[6, 7], breastfeeding [8], infections [9–11], antibiotics [12,
13] and non-steroidal anti-inflammatory drugs (NSAIDs)
[14], and diet [15].
Only in recent years the potential relationship between
nutritional intake and IBD has been increasingly explored
[15, 16]. A recent large prospective study revealed a pro-
tective effect of high dietary fiber intake, above all from
fruit, for CD [17]. While the development of CD was asso-
ciated with the intake of total fats and consumption with
sugar and/or sweeteners [18, 19], a similar association was
found between UC and monounsaturated and polyunsat-
urated fat consumption [20].
Coffee as one of the most popular beverages worldwide
and especially in the Western countries has recently
gained attention, when its positive effects were described
for a variety of chronic diseases, such as liver diseases
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(including hepatitis C and non-alcoholic fatty liver dis-
ease) [21–24], type 2 diabetes mellitus [25, 26], Parkinson’s
disease [27], constipation [28], and cancer [29, 30]. The
probably largest prospective study on this topic showed
inverse associations of coffee consumption with overall
mortality and specifically with death due to heart disease,
respiratory disease, stroke, injuries and accidents, diabetes,
and infections [31].
Coffee represents a highly complex mixture of different
compounds, containing more than a thousand different
chemical constituents, including carbohydrates, lipids,
nitrogenous compounds, vitamins, minerals, alkaloids and
phenolic compounds and providing significant amounts of
chlorogenic acid and caffeine [32]. However, in view of
their concentration in the brew, previous studies on detec-
tion of causal compounds or metabolites in the body and
physiological effects, only three highly abundant ingredi-
ents appear to be of importance: caffeine (1,3,7-trimethyl-
xanthine, a purine alkaloid) [32], the diterpene alcohols
(cafestol and kahweol) as well as chlorogenic acid and
other polyphenols [33, 34] Regarding the GIT, the effects
of coffee and caffeine are increasingly explored. At typical
daily intake levels, caffeine appears to exert biological
effects through the antagonism of the A1 and A2A
subtypes of the adenosine receptor [35]. Adenosine is
an endogenous neuromodulator with mostly inhibitory
effects, and adenosine antagonism by caffeine that results
in effects that are generally stimulatory [36]. Moreover,
coffee has prebiotic effects but also antibacterial activity
inducing alterations in intestinal microbiota such as a
decrease in E. coli and Clostridium spp. as well as an
increase in Lactobacillus spp.and Bifidobacterium spp.
[37, 38]. In addition, effects on gastrointestinal motility
including stimulation of colonic motor activity [39] and
increase in rectal tone [40] have been described. A re-
cent patient survey indicated a protective effect of cof-
fee consumption on the risk of developing primary
sclerosing cholangitis [41].
Despite the plurality of the aforementioned findings
on coffee in gastrointestinal medicine and despite the
fact that coffee is one of the most ubiquitously con-
sumed beverages all over the world, the potential role
of coffee intake on the course of disease in IBD has
not been investigated so far. Using a patient survey in
a large collective of IBD patients in Switzerland, we
aimed to investigate the consumption behavior and
perception among IBD patients towards coffee.
Methods
Study cohort and questionnaire
This questionnaire-based patient survey was conducted
among patients with known CD and UC or IBD unclassi-
fied (IBDU) from the Swiss Crohn’s and Colitis Patients As-
sociation (SMCCV,) with roughly 2000 members. Between
December 2012 and May 2013, all members were informed
about the questionnaire in the regularly published print
journal of the SMCCV as well as on the SMCCV homepage
and were invited to participate via conventional mail or
web-based on a voluntary basis without receiving any fi-
nancial recompensation. Inclusion in the survey ended in
May.2013. The study participants were asked to answer a
short questionnaire consisting of 4 questions on their con-
sumption and perception of coffee regarding possible im-
pact on their symptoms (the full questionnaire is provided
in the appendix, Additional file 1: Table S1). Patients’ data
were anonymized.
Statistics
The answers were analyzed by means of descriptive
statistics. Comparison between CD and UC patients
were performed using chi square testing, p-values of less
than 0.05 were considered statistically significant. The
statistical analyses were performed using SPSS (Version
21; IBM, Armonk, NY, USA).
Results
A total of 497 IBD patients representing nearly 25 % of
all members of the SMCCV answered our survey, in-
cluding 330 (66.4 %) patients with CD, 157 (31.6 %) with
UC, and 10 (2 %) with IBD unclassified (IBDU). Due to
inappropriate responses, 55 questionnaires had to be
excluded from further analysis.
Coffee drinkers among IBD patients
Out of 442 patients included for data analysis, 321
(72.6 %) patients regularly consumed coffee (Fig. 1). This
distribution appeared very similar in the subtypes of IBD
(CD 72.6 %, UC 72.8 %, IBDU 71.4 %; Fig. 1).
The vast majority of regular coffee drinkers (300/321;
93.5 %) preferred coffee with caffeine, while only 6.5 %
(21/321) of patients consumed coffee without caffeine.
Among IBD subtypes there were no significant differ-
ences between patients who drank coffee with or with-
out caffeine, as well as between those who negated
drinking coffee regularly: 67.9 % of CD patients (195/
288), 67.7 % (195/288) of patients with UC, and 71.4 %
(5/7) of patients with IBD unclassified declared drink-
ing regularly caffeinated coffee, while roughly 5 % in
each patient group preferred decaffeinated coffee, and
about 28 % did not consume coffee at all or only unre-
gularly (Fig. 1).
Reasons not to consume coffee regularly
Those patients refraining from regular coffee intake
were asked for their reason(s) to disclaim coffee. Over-
all, nearly two thirds (75/121) 62 %) of IBD patients
were convinced that consuming coffee would have a
negative impact on their intestinal symptoms, while
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35.5 % (43/121) referred to “any other reasons” for not
drinking coffee, and 2.5 % (3/121) of the patients
stated that they did not know why they passed on cof-
fee (Fig. 2). Of note, significant differences between
the IBD subtypes were seen. While the majority of pa-
tients with CD and IBDU (together 76.4 % 52/68)
found that coffee had a negative effect on their dis-
ease, only 44.4 % of UC patients (23 of 53) shared this
view (p = 0.002).
IBD patients’ perception of coffee on their bowel disease
All participants (i.e. coffee-drinkers and non-coffee-
drinkers) were asked to give their general opinion
whether regular coffee intake exerts a positive, negative
or no influence at all on their bowel symptoms. In total
38 % of IBD patients (168/442) assumed that coffee
does have an overall effect on their symptoms, signifi-
cantly more in CD than UC (53.5 % vs 22 %; p < 0.001,
Fig. 3). Strikingly and highly significant, more than
twice as many CD patients (45.2 %) felt that coffee
negatively influences their course of disease by worsen-
ing intestinal symptoms, as compared to only 20.2 % of
UC patients (p < 0.001). Among CD roughly an equal
amount of patients (43.3 %) as those stating an adverse
influence of coffee did not attribute any effect on coffee
on the course of their condition at all. This fraction of
patients not identifying any disease modifying effect of
coffee intake on the course of their IBD is significantly
higher in UC (75.7 %; p < 0.001).
We next analyzed whether the individual experience
on the effect of coffee on the disease course had an im-
pact on coffee consumption. Therefore, we stratified
current coffee consumption according to patients’ self-
reported impression on the impact of coffee intake on
the course of their disease. As expected, significantly
more patients, attributing a positive impact to coffee
report regular coffee intake compared to their counter-
parts attributing a negative effect (p < 0.001). However,
there is a high fraction of patients that regularly con-
sumed coffee (49.1 % in total; 41.7 % and 7.4 % with
and without caffeine, respectively) even in the subgroup
of IBD patients that assigned a negative impact of cof-
fee consumption on their symptoms (Fig. 4).
Discussion
This questionnaire-based patient survey investigated the
consumption behavior and perception among 442 IBD
patients of the Swiss Crohn’s and Colitis Patient Associ-
ation towards coffee. While there has been long-standing
extensive research on the role of environmental fac-
tors, such as smoking, childhood infectious diseases
Fig. 1 Coffee consumption in 442 IBD patients. Almost three quarters of patients (72.6 %) regularly consume coffee (93.5 % caffeinated coffee,
6.5 % decaffeinated coffee). This distribution appears very similar in CD, UC and IBDU (209 of 288, 72.6 % of CD, 107 of 147, 72.8 % of UC and 5
of 7, 71.4 % of IBDU patients; IBD: Inflammatory bowel disease, CD: Crohn’s disease, UC: ulcerative colitis, IBDU: IBD unclassified)
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Fig. 3 IBD patients’ perception about the effect of regular coffee consumption on their intestinal symptoms. Significantly more patients with CD
think that coffee has an overall impact on their bowel disease, compared to UC patients as depicted by brackets combining patients attributing a
positive and a negative effect. Among UC patients, the majority (about three quarters of patients) do not think that coffee has any influence at all
on their symptoms. Uniformly among all IBD subtypes, if an impact of coffee on disease symptoms is attributed by patients, only a small minority
of patients experience a positive influence
Fig. 2 Reasons for 121 IBD patients not to drink coffee. 60 % of those patients mentioned that they fear negative impact on their bowel disease.
30 % mentioned “other reasons” meaning any reason apart from the former reason. The analysis for the separate IBD subgroups show, that,compared
to UC patients, both CD and IBDU patients much more often stated not drinking coffee because they experience a negative influence of coffee on
their symptoms of disease
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and antibiotic intake [9–13], only in recent years a
growing number of investigations shed some light on
the potential role of dietary factors on IBD pathogen-
esis and their potential disease modifying effect [15,
16]. Interestingly, despite the fact that coffee is one of
the most ubiquitous consumed beverages all over the
world [31] containing a magnitude of ingredients with
the potential to exert a wide spectrum of biological ef-
fects, there is only very scant data on the interrelation
of coffee consumption and IBD. To the best of our
knowledge, this is the first study in humans focusing on
coffee consumption and IBD patients’ perception re-
garding their clinical bowel symptoms.
One of the key findings of our survey is the fact, that
more than two thirds of all IBD patients regularly con-
sume coffee. While the general per capita consumption
of coffee in Switzerland with 7.85 kg per year is among
the highest in Europe [42], there is no authoritative data
on percentages of the general population in Switzerland
regularly consuming coffee. However, the 72.6 % of
Swiss IBD patients consuming coffee appear to be in a
comparable dimension with recent data from the general
population: 83 % of US adults state to drink coffee, 63 %
and 75 % declare to consume it daily and at least once
per week, respectively [43].
Interestingly, while the subtype of IBD does not appear
to be associated with coffee consumption overall, there
are significant differences in the perceived effect of
coffee on intestinal symptoms between patients with CD
and UC. Firstly, the fraction of patients attributing any
disease-modifying capacity of coffee at all is more than
twice as high in CD compared to UC (53.5 % vs. 22 %,
respectively). Secondly, in both IBD subtypes the vast
majority of those patients attributing a disease-modifying
effect of coffee identified this effect as being a negative
one. Nevertheless, this number significantly is divergent
between IBD subtypes, with only about one in five UC pa-
tients but almost every second CD patient stating, that
coffee intake adversely affects course of their disease.
Interestingly, the negative patient’s perception of regu-
lar coffee intake on the course of disease did not lead to
complete abstinence. Quite the contrary, a notably high
fraction of patients (almost every second patient) per-
ceiving coffee to negatively affect their course of disease
did not refrain from regular coffee intake.
Our study has several limitations. With our unvalid-
ated questionnaire we did not obtain specific data re-
garding disease localization, disease activity, medical
therapy or data on quantitative average coffee intake as
well as consume of other substances with or without
caffeine such as tea and certain caffeine-containing soft-
drinks or alcohol and cigarette smoking, respectively.
However, the focus of this questionnaire was to give an
impression about the frequency of coffee drinkers
among a large number of unselected IBD patients and
their perception of coffee on bowel disease. In order to
achieve a number of replies as high as possible we de-
cided to maximally constrict the amount of questions
on the questionnaire, hence time needed for answering.
Moreover, we decided to recruit patients only from the
Swiss IBD patient organization representing the complete
spectrum of IBD patients throughout Switzerland, thus
Fig. 4 Regular coffee consumption according to the attributed impact on IBD symptoms. While it is not surprising, that the fraction of patients
regularly drinking coffee is high in those patients identifying a positive impact and also no impact of coffee on their IBD, the fact that almost
every second patient in the group identifying a negative influence of coffee nevertheless regularly consumes this beverage is noteworthy
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minimizing a potential selection bias, that would likely
occur if patients were recruited by their treating physi-
cians or IBD nurses in larger hospitals or tertiary referral
centers. Unfortunately, we believe, that such a selection
bias may be an important confounder in several pub-
lished survey studies, where patients from larger cen-
ters are notoriously overrepresented.
In view of the finding that our patients rather dis-
tinctively ascribe a negative effect to regular coffee con-
sumption (if an effect is ascribed at all), drawing any
conclusions derived from previous in vitro and in vivo
research of coffee or specific coffee ingredients with
regards to the potential direction and mechanisms
underlying the interrelation of coffee and IBD with the
current state of knowledge is challenging. On the one
hand there are some studies that showed a pro-
inflammatory effect of coffee in the intact human gut,
with an activation of NF-ĸB [44, 45]. Moreover, the
stimulatory effects on gastrointestinal motility [39]
might simply increase stool frequency and thus ad-
versely affect IBD symptoms. On the other hand, other
previous findings rather suggest a protective efficacy of
coffee in IBD through anti-inflammatory [41, 46, 47] and
anti-neoplastic [29, 46, 48] properties.
Although the discrepancy between CD and UC pa-
tients is striking, this survey does not provide any guid-
ance on the potential reasons behind the perceived
stronger negative impact of coffee consumption in CD
compared to UC. Nevertheless, it might be speculated,
that differences in the localization, role of microbial
composition, redox state, contribution of adaptive and
innate immunity as well as inflammatory pathways most
likely are underlying causative factors.
Evidently, a questionnaire-based survey cannot replace
a mechanistic prospective investigation. Nevertheless, the
results from various previous studies identifying effects of
coffee ingredients on inflammation (some however with
conflicting results) redox state, intestinal microbial com-
position and gastrointestinal motility in conjunction with
the results from our survey corporately indicate an over-
all disease-modifying potential of coffee in general or one
of its specific ingredients in IBD.
On the basis of our survey the question, why almost
every second IBD patient who attributed a negative in-
fluence of coffee intake on the bowel symptoms, never-
theless regularly consumed coffee, cannot be answered.
It may be speculated that the magnitude of the per-
ceived effect on the disease course is only limited, not
justifying or necessitating a complete abstinence. How-
ever, it might also be speculated, that the potential
negative impact is indeed well perceived, but ignored or
at least apportioned far less significance to. The latter
would at least partly fulfill characteristics of an addic-
tion, and in that be similar to active smoking in CD.
Finally this high fraction of regular coffee consumers
despite the perceived negative impact might also repre-
sent the current uncertainty on the exact role of coffee
consumption on their symptoms due to the paucity of
literature with regards to IBD, while the literature on
coffee and a multitude of other gastrointestinal and
general medical disease states has intriguingly increased
and mostly suggested beneficial properties of coffee or
specific coffee components [21–31].
Thus, these findings call for further controlled in vitro
and in vivo studies to investigate the effect of coffee
consumption in IBD as well as the observed divergence
between CD and UC, including controlled trial in
humans using clinical and biochemical endpoints.
Conclusions
In conclusion, we showed that a substantial fraction of
IBD patients identify regular coffee consumption as an
impacting factor on their intestinal symptoms. An over-
all influence is significantly more often attributed to
coffee in patients with CD. In addition, in these CD pa-
tients a significantly higher fraction is convinced that
coffee adversely affects their intestinal symptoms com-
pared with their counterparts with UC, where most pa-
tients do not identify a correlation between coffee and
their disease. However, a negative perception on the
effect of coffee on the course of disease, if present, does
not appear to translate into an abstinence from coffee
consumption.
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